3SBIO (01530) surged 8% in early trading, reaching HK$29.46 with a turnover of HK$381 million by the time of reporting. The uptick follows news that Pfizer (PFE) registered two global Phase III clinical trials for its PD-1/VEGF bispecific antibody PF-08634404 (SSGJ-707) on Clinicaltrials.gov on October 30. The trials will evaluate the drug in combination with chemotherapy for advanced non-small cell lung cancer (head-to-head against Keytruda + chemotherapy) and metastatic colorectal cancer.

In May, Pfizer secured rights to 3SBIO's PD-1/VEGF bispecific antibody for an upfront payment of $1.25 billion, up to $4.8 billion in milestone payments, and double-digit percentage royalties on sales. Cinda Securities noted in a research report that SSGJ-707 has the potential to become a cornerstone therapy in global oncology. The firm expects Pfizer to swiftly advance global Phase III trials for NSCLC and other solid tumors while exploring additional monotherapy and combination regimens, including with ADCs, across other cancer types.